CL2025001901A1 - Uso de pridopidina para el tratamiento de la enfermedad de huntington juvenil. - Google Patents

Uso de pridopidina para el tratamiento de la enfermedad de huntington juvenil.

Info

Publication number
CL2025001901A1
CL2025001901A1 CL2025001901A CL2025001901A CL2025001901A1 CL 2025001901 A1 CL2025001901 A1 CL 2025001901A1 CL 2025001901 A CL2025001901 A CL 2025001901A CL 2025001901 A CL2025001901 A CL 2025001901A CL 2025001901 A1 CL2025001901 A1 CL 2025001901A1
Authority
CL
Chile
Prior art keywords
pridopidine
disease
treatment
juvenile huntington
huntington
Prior art date
Application number
CL2025001901A
Other languages
English (en)
Inventor
Hayden Michael
Geva Michal
Paul Goldberg Yigal
Original Assignee
Prilenia Neurotherapeutics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Prilenia Neurotherapeutics Ltd filed Critical Prilenia Neurotherapeutics Ltd
Publication of CL2025001901A1 publication Critical patent/CL2025001901A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/451—Non condensed piperidines, e.g. piperocaine having a carbocyclic group directly attached to the heterocyclic ring, e.g. glutethimide, meperidine, loperamide, phencyclidine, piminodine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/452—Piperidinium derivatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Se proporciona en la presente un método de tratamiento de la enfermedad de Huntington juvenil en un sujeto que lo necesite que comprende la administración oral de una composición farmacéutica que comprende pridopidina y/o su análogo o una sal farmacéuticamente aceptable de los mismos.
CL2025001901A 2022-12-27 2025-06-25 Uso de pridopidina para el tratamiento de la enfermedad de huntington juvenil. CL2025001901A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US202263477227P 2022-12-27 2022-12-27

Publications (1)

Publication Number Publication Date
CL2025001901A1 true CL2025001901A1 (es) 2025-09-05

Family

ID=91716756

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2025001901A CL2025001901A1 (es) 2022-12-27 2025-06-25 Uso de pridopidina para el tratamiento de la enfermedad de huntington juvenil.

Country Status (10)

Country Link
US (1) US20260207575A1 (es)
EP (1) EP4642457A4 (es)
JP (1) JP2025541535A (es)
KR (1) KR20250121149A (es)
CN (1) CN120569199A (es)
AU (1) AU2023420087A1 (es)
CL (1) CL2025001901A1 (es)
IL (1) IL321683A (es)
MX (1) MX2025007590A (es)
WO (1) WO2024142058A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2026035949A1 (en) * 2024-08-08 2026-02-12 Prilenia Therapeutics Inc. Combination of pridopidine and low dose anti-dopaminergic medication (adm) for treating huntington disease and sympto thereof

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11090297B2 (en) * 2013-06-21 2021-08-17 Prilenia Neurotherapeutics Ltd. Pridopidine for treating huntington's disease
CN110012661A (zh) * 2016-08-24 2019-07-12 普瑞尼亚医疗发展有限公司 普利多匹定用于治疗肌张力障碍的用途
JP2020532517A (ja) * 2017-08-30 2020-11-12 プリレニア ニューロセラピューティクス リミテッド 高濃度プリドピジン製剤
SMT202600016T1 (it) * 2019-06-12 2026-03-09 Prilenia Neurotherapeutics Ltd Composizione contenente pridopidina e un suo analogo per il trattamento della malattia di huntington e dei suoi sintomi
AU2021366505A1 (en) * 2020-10-20 2023-06-01 Prilenia Neurotherapeutics Ltd. Use of pridopidine and analogs for the treatment of anxiety and depression

Also Published As

Publication number Publication date
US20260207575A1 (en) 2026-07-23
EP4642457A4 (en) 2026-04-08
AU2023420087A1 (en) 2025-07-10
WO2024142058A1 (en) 2024-07-04
JP2025541535A (ja) 2025-12-18
IL321683A (en) 2025-08-01
EP4642457A1 (en) 2025-11-05
KR20250121149A (ko) 2025-08-11
CN120569199A (zh) 2025-08-29
MX2025007590A (es) 2025-08-01

Similar Documents

Publication Publication Date Title
AR020803A1 (es) Una composicion que comprende fexofenadina o una sal farmaceuticamente aceptable de la misma y el uso de la misma para la manufactura de unmedicamento
MX2019008853A (es) Metodos para la administracion de ciertos inhibidores de proteina transportadora transportador de monoamina vesicular-2 (vmat2).
CU23468B7 (es) Forma de dosificación de pramipexol en una dosis única diaria
AR013506A1 (es) Uso de una composicion farmaceutica para la manufactura de un medicamento para ser usado en el tratamiento de enfermedades de obstruccion pulmonarcronica y de un kit que comprende formoterol o una sal o solvato del mismo y budesonida
BRPI0408256A (pt) composto, métodos de tratamento de um humano ou animal, pela limitação da replicação de células, que sofre de cáncer, que sofre de uma doença neoplástica, e que se sofre de doenças proliferativas, uso de um composto, e, processo para a preparação de um composto ou de um seu sal farmaceuticamente aceitável ou de um éster hidrolisável in vivo do mesmo
ES2188782T3 (es) Formulaciones farmaceuticas que contienen darifenacina.
MX2015017307A (es) Uso de pridopidina en dosis altas para el tratamiento de enfermedad de huntington.
AR035927A1 (es) Compuesto de lactama (n)-((s)-2-hidroxi-3-metilbutiril)-1-(l-alaninil)-(s)-1-amino-3-metil-4,5,6,7-tetrahidro-2h-3-benzazepin-2-ona , composicion farmaceutica que lo comprende, procedimiento para la inhibicion de la liberacion de peptido b-amiloide y/o su sintesis que lo emplea y su uso para la fabr
BR0307540A (pt) Preparação farmacêutica em forma de filme ou em forma de lâmina para administrar substâncias ativas, uso da preparação farmacêutica e processo para a administração oral de substância(s) farmaceuticamente ativa(s) dotadas de sabor amargo
CL2021003312A1 (es) Composición que comprende pridopidina y un análogo de la misma para el tratamiento de la enfermedad de huntington y síntomas de la misma.
CO4750658A1 (es) Formulaciones farmaceuticas y procedimientos que comprenden amoxicilina y una sal de acido clavulanico
AR008306A1 (es) Uso de amoxicilina y clavulanato en la fabricacion de un medicamento
UY39510A (es) Compuestos macrocíclicos y métodos para usarlos
ES2570401T3 (es) Métodos de tratamiento usando dosis únicas de oritavancina
AR045289A1 (es) Forma de dosificacion oral de liberacion controlada que comprende 4-(2-di-n-propilaminoetil) - 2(3h)-indolona (ropi-nirol) y uso de dicha forma de dosificacion para la elaboracion de un medicamento
ATE113834T1 (de) Zusammensetzung zur behandlung der schizophrenie.
UY29085A1 (es) Derivados de pirimidina 4-sulfonamido sustituidos, compuestos intermedios para su preparación, procedimientos de preparación, composiciones medicinales conteniéndolos y aplicaci0nes
AR036312A1 (es) Composicion farmaceutica
AR046036A1 (es) Composiciones de risedronato y metodos para su uso
AR041947A1 (es) Uso de acetil-l-carnitina o de una sal farmaceuticamente aceptable de la misma para la preparacion de un medicamento para prevenir y/o tratar las neuropatias perifericas inducidas por la administracion de un agente anticancer que induce neuropatias perifericas
AR029666A1 (es) Uso del (+) -alfa-(2,3-dimetoxifenil)-1-[2-(4-fluorofenil)etil]-4-piperidinmetanol o su prodroga para la manufactura de un medicamento en el tratamiento de los sintomas de la demencia y de la psicosis inducida por dopamina
BRPI0518741A2 (pt) uso de uma combinaÇço de uma droga diretamente metabolizada por ugt1a1 ou um seu sal farmaceuticamente aceitÁvel e atazanavir ou um seu sal farmaceuticamente aceitÁvel, e, combinaÇço farmacÊutica para administraÇço oral a um mamÍfero
MX2025007590A (es) Pridopidina para el tratamiento de la enfermedad de huntington juvenil
CL2025002663A1 (es) Formulaciones de dosis de una sola unidad de alta concentración y métodos de uso de estas
AR052830A1 (es) Regimen de cladribina para tratar esclerosis multiple